US firm Alkomex expands R&D ops in India; ropes in expert Sanjay Agrawal

Agrawal will be based in Ahmedabad and will spearhead the US firm's research and strategic initiatives, it said, adding that he will guide the company's R&D efforts and integrate Indian research

Prices of active pharmaceutical ingredients (APIs) have been declining over the past several months, boosting the margins of drug manufacturers. However, many industry insiders attribute this to a predatory pricing strategy by Chinese companies, and
Nutraceuticals are foods, ingredients, or dietary supplements that may have health or medical benefits. (Representative Picture)
Press Trust of India Mumbai
1 min read Last Updated : Nov 04 2024 | 6:00 PM IST

Global pharma company Alkomex GBN looks to expand its research and development footprint in India and has roped in nutraceuticals expert Sanjay Agrawal to spearhead its strategic initiatives in the country, a statement said on Monday.

Alkomex GBN has formed a partnership with Dr Sanjay Agrawal, a renowned Indian expert in health management and nutraceuticals, and has appointed him as the Scientific Advisor for Alkomex GBN, the statement said.

"His leadership will be instrumental in driving our growth as we continue to expand our footprint in the nutraceutical and functional food sectors," Alkomex CEO Alex Meneses Vega said.

Agrawal will be based in Ahmedabad and will spearhead the US firm's research and strategic initiatives, it said, adding that he will guide the company's R&D efforts and integrate Indian research into Alkomex's global operations.

The partnership is expected to significantly strengthen Alkomex GBN's capabilities in developing scientifically-backed nutraceuticals and functional food products designed to enhance global health and wellness, the company said.

Nutraceuticals are foods, ingredients, or dietary supplements that may have health or medical benefits.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :US firmsIndia's R&D spendingpharmaceutical firms

First Published: Nov 04 2024 | 6:00 PM IST

Next Story